CeMM Adjunct Principal Investigator
Hepatic microenvironment in disease progression and regression
Thomas Reiberger conducted seminal studies for optimizing the role of non-selective betablocker therapy in patients with cirrhosis and portal Hypertension (Reiberger, Gut, 2013; Mandorfer, Gastroenterology 2015; Reiberger, Journal of Hepatology, 2017). His HEPEX research team is focused on exploring novel treatment options for liver fibrosis and portal hypertension, such as anti-angiogenic drugs (Reiberger, Journal of Hepatology 2009), FXR agonsits (Schwabl, Journal of Hepatology, 2017) and soluble guanylate cyclase stimulators (Schwabl, Scientific Reports 2018). Thomas Reiberger is also the clinical director of the cirrhosis outpatient clinic and the Vienna Hepatic Hemodynamic Laboratory at the Division of Gastroenterology & Hepatology.
Main Research Interests:
- Liver fibrogensis and inflammation
- Portal hypertension
- Rare liver diseases causing non-cirrhotic portal hypertension
Thomas Reiberger joined the LBI-RUD and CeMM in November 2018 as an adjunct PI. After obtaining his MD at the Medical University of Vienna, he did a first postdoc at the Department of Pathophysiology at MedUni Vienna, focusing on ex-situ liver perfusion and studying hepatocyte oxidative stress and biliary transporters. During his residency for internal medicine, Reiberger pursued a career as a physician-scientist while conducting translational studies on portal hypertension, liver fibrosis, and viral hepatitis. In addition to his clinical activities, he established the Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory at MedUni Vienna. The main mission of his HEPEX research team is the exploration of novel treatment options for liver fibrosis and portal hypertension including anti-angiogenic drugs, FXR agonists, modulators of the soluble guanylate cyclase, and integrin inhibitors. In 2011, he received his venia docendi and in 2012 he obtained his board certification for internal medicine. After another postdoctoral fellowship in the United States from 2012 to 2015, Thomas Reiberger joined the faculty of the Division of Gastroenterology and Hepatology at MedUni Vienna. He conducted seminal clinical studies in the field of liver cirrhosis and portal hypertension. Thomas Reiberger is also the director of the clinical program for advanced chronic liver disease and transplant hepatology at the Vienna General Hospital. In his role as the coordinator of the Rare Liver Disease (RALID) Center of the European Reference Network (ERN) RARE-LIVER at the Vienna General Hospital, he complements the mission of the LBI-RUD with translational research on rare liver diseases.
Hartl L, Rumpf B, et al. The systemic and hepatic alternative reninangiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation. Sci Rep. 2023 Jan 18;13(1):953. (abstract)
Königshofer P et al. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology. 2022 Mar;75(3):610-622. (abstract)
Schwabl P et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodeling and sinusoidal dysfunction. J Hepatol. 2017 Apr;66(4):724-733. (abstract)
Reiberger T, et al. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017 Apr;66(4):849-859. (abstract)
Reiberger T et al. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Prot. 2015 Aug;10(8):1264-1274. (abstract)
Reiberger T, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013 Nov;62(11):1634-41. (abstract)
Reiberger T, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013 May;58(5):911-21. (abstract)
Reiberger T, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol. 2009 Nov;51(5):865-73. (abstract)